Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer

The PROpel trial assessed the combination of olaparib + abiraterone acetate (AA) plus prednisone and androgen deprivation therapy (ADT) versus AA plus prednisone and ADT alone as first-line treatment for metastatic castration-resistant prostate cancer (mCPRP). To contextualize the progression free s...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallara, Giuseppe, Robesti, Daniele, Raggi, Daniele, Montorsi, Francesco, Necchi, Andrea, Cooperberg, Matthew R., Malavaud, Bernard, Ploussard, Guillaume, Martini, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172739/
https://www.ncbi.nlm.nih.gov/pubmed/37182120
http://dx.doi.org/10.1016/j.euros.2023.03.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172739/
https://www.ncbi.nlm.nih.gov/pubmed/37182120
http://dx.doi.org/10.1016/j.euros.2023.03.009

Ejemplares similares